Pharmaceuticals company Bajaj Healthcare announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations increased by 15.4%, rising to Rs 1,544.7 million from Rs 1,339.0 million. Gross Profit rose significantly by 30.8% to Rs 740.8 million from Rs 566.5 million. EBITDA grew by 12.6% to Rs 253.3 million from Rs 224.9 million. EBITDA Margin (%) declined slightly to 15.1% from 16.0%. Profit for the period turned positive at Rs 111.8 million, compared to a loss of Rs (299.2) million in Q4 FY24. FY25 Financial Highlights: Revenue from Operations increased by 14.6% to Rs 5,426.0 million from Rs 4,734.2 million. Gross Profit improved by 21.2% to Rs 2,755.6 million from Rs 2,273.3 million. EBITDA grew by 19.9% to Rs 1,018.3 million from Rs 849.5 million. EBITDA Margin (%) rose slightly to 18.1% from 17.6%. Profit for the period turned around to a profit of Rs 395.0 million, compared to a loss of Rs (837.9) million in FY24. Commenting on the Results, Anil Jain – Managing Director said, “FY25 has been a transformational year for Bajaj Healthcare. We have delivered a strong financial turnaround and regained profitability, reflecting our commitment to operational discipline and long-term value creation. We closed the year with a net profit of Rs 395 million, a significant swing from losses in the previous year. Gross margin expanded to 49%, supported by a more favorable product mix. EBITDA grew by 20% year-on-year, outpacing revenue growth and reflecting the benefits of improved operating leverage and cost efficiencies. Despite headwinds in the API segment across the industry, I am proud to share that we achieved approximately 8% year-on-year revenue growth in our overall API business in FY25. Our Formulations segment also delivered exceptional year-on-year revenue growth of 69% during the same period. These gains reflect the strategic realignment of our portfolio and improved utilization across key facilities. A key development was the acquisition of Genrx Pharmaceuticals Pvt. Ltd., possession of which was taken in April 2025, significantly enhancing our manufacturing infrastructure and enabling future portfolio expansion. From a product innovation standpoint, we continue to build a differentiated pipeline in CNS and wellness categories. The launch of Pimavanserin and the progress of Cenobamate toward final regulatory approval reflect our ability to deliver niche and high-impact therapies in India. We also made significant headway in expanding our presence in regulated international markets. With new CDMO partnerships and regulatory clearances now in place, we are on track to become a credible outsourcing partner for global pharma. Our exports currently account for 24% of total revenue, and with these new partnerships, we aim to substantially increase our export share going forward. We enter FY26 with renewed momentum, a differentiated pipeline, and scalable capacity across APIs, formulations, and CDMO. We are committed to building Bajaj Healthcare into a trusted global pharmaceutical partner through innovation, regulatory strength, and operational excellence.” Result PDF